News

Vinay Prasad returns to US' FDA, resumes role overseeing vaccine, gene therapy, STAT News reports
Vinay Prasad is returning to his role at the U.S. Food and Drug Administration to resume overseeing vaccine, gene therapy and ...
Vinay Prasad returns to US' FDA, resumes role overseeing vaccine, gene therapy
Vinay Prasad is returning to his role at the U.S. Food and Drug Administration, a little more than a week after he had left ...
MedPage Today on MSN1d
FDA Restricts Gene Therapy Skysona Due to Blood Cancer Risk
The FDA approved labeling changes for elivaldogene autotemcel (eli-cel; Skysona), a one-time gene therapy for patients with ...
As gene therapies falter on the market, this biopharma is aiming to defy the odds
After a strong launch for its cancer gene therapy, Ferring Pharmaceuticals is setting the stage for long-term growth.
STAT1h
Vinay Prasad returns to the FDA, weeks after his ouster
WASHINGTON — Vinay Prasad is returning to the Food and Drug Administration to resume his role overseeing vaccine, gene ...
China Daily2d
China's gene therapy research making strides to restore sight for RP patients
Currently, GenAns Biotech is conducting investigator-initiated trials for several gene therapies, including GA001 for ...
FDA Chief Says He Wants Gene Therapy Head Prasad to Return
US Food and Drug Administration Commissioner Marty Makary said he’s trying to persuade Vinay Prasad, the agency’s former head ...
CGT Global Appoints Dr. Andrew Branagan to Board of Advisors, Expanding Cell and Gene Therapy Expertise
CGT Global, a leading biotechnology company driving the development and delivery of innovative cell and gene therapies, today ...
Sarepta reportedly hired Trump-linked lobbying firm after gene therapy deaths
Sarepta Therapeutics (SRPT) stock in focus as report says company hired a Trump-linked lobbying firm after deaths linked to ...
EurekAlert!3d
Breakthrough gene therapy for neovascular age-related macular degeneration shows promise in animal models and patients
A groundbreaking study titled "An Engineered Intravitreal Injection Retinal-Pigment-Epithelium-Tropic Adeno-Associated Virus ...
GEN - Genetic Engineering and Biotechnology News3d
3 BLAs in 3 Years: Ocugen Sees Potential in Eye Disease Gene Therapies
Ocugen says it is on track to reshape the market for gene therapies against eye disorders over the next three years, by ...
Rocket (RCKT) Q2 Loss Narrows 16%
Net loss per share (GAAP) was $0.62, but remained negative as the company continues to invest heavily in research and development. The pivotal Phase 2 trial for Danon disease was placed on clinical ...